AstraZeneca (LON: AZN) has acquired key technology assets from Achilles Therapeutics (NASDAQ: ACHL), including proprietary data and samples from the TRACERx study and the Material Acquisition Platform (MAP), for $12 million.
The deal signals the conclusion of a strategic review by Achilles, announced in September 2024.
The TRACERx (TRAcking Cancer Evolution through therapy (Rx)) study is one of the largest tumour evolution projects.
The company said it has generated genetic data from over 3,200 tumour samples across 800 patients with non-small cell lung cancer (NSCLC).
As part of the agreement, AstraZeneca will also assume sponsorship of Achilles’ MAP, which has collected tumour tissue and blood samples from nearly 300 cancer patients across multiple solid tumour types.
Dr Iraj Ali, CEO of Achilles Therapeutics, commented, “We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets.
“We believe that these assets have the potential to positively impact Oncology R&D and will support the development of new and improved therapies for cancer patients.”
The company said it will now undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- eToro Wide range of instruments available to trade – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
